Dr Inaya Mohamad Hazime, PHARMD | |
9321 Starting Gate Ct, Wilton, CA 95693-9249 | |
(916) 690-8496 | |
Not Available |
Full Name | Dr Inaya Mohamad Hazime |
---|---|
Gender | Female |
Speciality | Pharmacist |
Location | 9321 Starting Gate Ct, Wilton, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962850495 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
183500000X | Pharmacist | RPH43977 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Inaya Mohamad Hazime, PHARMD 1600 Eureka Rd, Roseville, CA 95661-3027 Ph: (916) 784-4332 | Dr Inaya Mohamad Hazime, PHARMD 9321 Starting Gate Ct, Wilton, CA 95693-9249 Ph: (916) 690-8496 |
News Archive
The week before and two weeks after surgery are a critical period for the long-term survival rate of cancer patients. Physiological and psychological stresses caused by the surgery itself can inhibit the body's immune responses, heightening vulnerability to tumor progression and spreading.
One of two dozen major trauma centers named to be a part of the Department of Defense-funded Major Extremity Trauma Research Consortium (METRC), Saint Louis University will work to improve treatment for wounded service members and civilians. The partnership aims to conduct research to improve the care of major orthopaedic injuries sustained on the battlefield.
Centers for Medicare & Medicaid Services (CMS) Administrator Mark McClellan, M.D., Ph.D. today announced CMS will soon undertake a pilot program in partnership with hospitals in 13 states and the District of Columbia to determine the effectiveness of the voluntary compliance programs used by many hospitals.
A new study describes inadequate antibody responses to the Pfizer/BioNTech vaccine against coronavirus disease 2019 (COVID-19) in elderly residents of a care home with no prior history of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), compared to those with such a history. This adds to the current understanding of vaccine efficacy against infection.
› Verified 3 days ago